accountMALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC'), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Reaction Biology Launches Recombinant Methyltransferase Line - Drugs and Pharmaceuticals News
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account